Envestnet Asset Management
OREX

Envestnet Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Envestnet Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-80
Closed -$5K – 2706
2014
Q4 		$5K Buy
+80
New +$4.02K ﹤0.01% 2175
2013
Q3 		– Sell
-30
Closed -$2K – 2577
2013
Q2 		$2K Buy
+30
New +$1.85K ﹤0.01% 2175

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Envestnet Asset Management's OREX Position: Q1 2015 in Review

Envestnet Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 80 shares — an estimated $5K sold.

Envestnet Asset Management first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $5K in Q4 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

  • Envestnet Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Envestnet Asset Management sold 80 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $5K.
  • Envestnet Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Envestnet Asset Management's Orexigen Therapeutics, Inc. position peaked at $5K in Q4 2014.
  • 160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Envestnet Asset Management's 13F filing for Q1 2015, filed 15 May 2015.